Drugs & TargetsFree MIODx licenses immunotherapy technologies from UCSF February 24, 2017Vol.43 No.08
Drugs & Targets Amgen submits Supplemental Biologics License Application for Blincyto February 17, 2017Vol.43 No.07
Drugs & Targets Pan-Canadian Pharmaceutical Alliance, BMS reach agreement on Opdivo February 17, 2017Vol.43 No.07
Drugs & Targets Immunomedics enters into licensing agreement with Seattle Genetics for Sacituzumab Govitecan February 17, 2017Vol.43 No.07
Drugs & Targets FDA approves Opdivo for urothelial carcinoma indication February 10, 2017Vol.43 No.06
Drugs & Targets GenomeDx, Astellas work to identify genomic drivers of Xtandi response February 10, 2017Vol.43 No.06
Drugs & Targets MD Anderson, Guardant form partnership to make liquid biopsy standard of care February 03, 2017Vol.43 No.05
Drugs & Targets Addario institute and Scancell form partnership focused on vaccine February 03, 2017Vol.43 No.05
Drugs & Targets Perthera enters collaboration with Novartis to identify patients for clinical trials February 03, 2017Vol.43 No.05
